Home › Uterine Cancer › Minnesota › Minneapolis
Uterine Cancer clinical trials in Minneapolis, MN
3 studies for Uterine Cancer are looking for participants at sites in and around Minneapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer
RecruitingPhase 4
- M Health Fairview Clinics and Surgery Center, Minneapolis
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
RecruitingPhase 3
- Research Site, Minneapolis
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Minneapolis
About Uterine Cancer
Uterine cancer is a cancer that forms in tissues of the uterus. It is more likely to happen after menopause. There are things you can do that may help lower your risk.
More about Uterine Cancer on MedlinePlus
Uterine Cancer trials in other cities
- Houston, TX8 studies
- New York City, NY6 studies
- Columbus, OH6 studies
- Boston, MA5 studies
- Philadelphia, PA5 studies
- Austin, TX5 studies
- Miami, FL5 studies
- Pittsburgh, PA4 studies
- West Palm Beach, FL4 studies
- Providence, RI4 studies
- Orlando, FL4 studies
- Chicago, IL4 studies
Other studies in Minneapolis
- Non-Small Cell Lung Cancer27 studies
- Breast Cancer27 studies
- Ovarian Cancer24 studies
- Prostate Cancer23 studies
- Cancer (all types)22 studies
- Heart Failure21 studies
- Acute Myeloid Leukemia20 studies
- Lung Cancer20 studies
- Colorectal Cancer19 studies
- Endometrial Cancer18 studies
- Parkinson's Disease17 studies
- Cardiovascular Disease15 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.